



## **Auxellence Begins Doctor Supervised Study of its TULIP™ Online Self-Care Services for Medical Control of Weight, Blood Pressure, and Diabetes**

VANCOUVER, BC, Wednesday June 8<sup>th</sup>, 2016 – Auxellence Health Corporation (CSE: AID, OTCQB: AXHLF) (“Auxellence” or the “Company”) announces the start of the Stage II Commercial Pilot and Clinical Study of its online self-care system (TULIP™).

The one-year study will enroll up to fifty Canadian, physician-supervised patients. The focus will be on normalizing body weight, blood pressure, and blood glucose, as well as monitoring adverse events.

The study will evaluate the TULIP™ system in terms of scalability, interoperability, and marketability, as well as real-life, end-to-end system performance. Any additional benefits will be documented.

“Following the success of the Pioneer Pilot Program, we are now ready to survey the opportunities of providing TULIP™ self-care services to doctor-supervised patients. We want to study the impact factor of TULIP™ on the patients’ daily routines, as they seek to normalize their body weight, blood pressure, and blood glucose levels”, said Sydney Au, Chairman and CEO.

### **Contact:**

Sydney Au, CEO

Auxellence Health Corporation

Email: [ceo@auxellence.com](mailto:ceo@auxellence.com)

Phone: (604) 780-3311

Website: <http://www.auxellence.com>

CSE Micro-site: <http://thecse.com/en/listings/technology/auxellence-health-corporation>

### **About Auxellence Health Corporation (CSE: AID, OTCQB: AXHLF)**

Auxellence is a technology company engaged in the provision of medical monitoring, diagnostics, therapeutics and biomedical online services for common health problems. The company offers an extensive platform for physiologically interactive computing supporting therapeutic-diagnostic (theranostic) devices, expert systems, and recommender applications for personal health management (focusing on weight management and skin conditions).

### **About Tulip™**

TULIP™ is a medical device cleared for sales in Canada and Europe as a blood pressure monitor with interactive protocols. The device enables physiologically interactive health apps useful in testing, tracking, and treating common health conditions. The online system is aimed primarily at “practicing patients” interested in normalizing blood pressure, blood glucose, and body weight. Session schedules,



measurement procedures, and conditioning protocols are prescribed automatically by the system from extemporaneous data acquired from the user.

**Disclaimers – Forward Looking Statements**

This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators which is posted on [www.sedar.com](http://www.sedar.com), and on <http://thecse.com/en/listings/technology/auxellence-health-corporation>.

This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets Inc), nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.